Annovis Bio’s Promising Alzheimer’s Drug Trial: What Investors Need to Know

Annovis Bio Inc ((ANVS)) announced an update on their ongoing clinical study.

Study Overview: Annovis Bio Inc. is conducting a clinical trial titled A 6-month & 18-month Prospective, Randomized, Placebo-controlled, Double-blind Dual Clinical Trial Investigating Efficacy and Safety of Buntanetap in Treating Participants of Early Alzheimer’s Disease. The study aims to evaluate the effectiveness and safety of the drug Buntanetap (also known as Posiphen) in improving cognition and function in adults aged 55-85 with early Alzheimer’s disease.

Intervention/Treatment: The intervention being tested is Buntanetap, a drug administered as a 30mg capsule taken orally once daily for 18 months. The purpose is to assess its impact on cognitive and functional improvement compared to a placebo.

Study Design: This Phase 3 study is interventional, with participants randomly assigned to either the Buntanetap or placebo group. The study employs a parallel intervention model and uses quadruple masking, meaning the participant, care provider, investigator, and outcomes assessor are all blinded to the treatment allocation. The primary purpose is treatment-focused.

Study Timeline: The study began on February 4, 2025. The primary completion and estimated completion dates have not been provided, but the last update was submitted on August 11, 2025. These dates are crucial for tracking the study’s progress and anticipating results.

Market Implications: The ongoing study could significantly impact Annovis Bio Inc.’s stock performance, especially if Buntanetap proves effective. Positive results may enhance investor confidence and position Annovis Bio as a leader in Alzheimer’s treatment, potentially affecting competitors in the pharmaceutical industry.

Closing Sentence: The study is currently recruiting, with further details available on the ClinicalTrials portal.